References
- Rosenwald A, Chuang EY, Davis RE, et al Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428–1434.
- Byrd JC, Gribben JG, Peterson BL, et al Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24:437–443.
- Lozanski G, Heerema NA, Flinn IW, et al Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278–3281.
- Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007;26:3644–3653.
- Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
- Lenz G, Wright G, Dave SS, et al Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
- Dunleavy K, Pittaluga S, Czuczman MS, et al Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069–6076.
- Alizadeh AA, Bohen SP, Lossos C, et al Expression profiles of adult T-cell leukemia–lymphoma and associations with clinical responses to zidovudine and interferon α. Leuk Lymphoma 2010;51:1200–1216.
- Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
- Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.
- Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev 2007;7:270–280.
- Tsukasaki K, Hermine O, Bazarbachi A, et al Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009;27:453–459.
- Hermine O, Bouscary D, Gessain A, et al Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995;332:1749–1751.
- Kchour G, Makhoul NJ, Mahmoudi M, et al Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma 2007;48:330–336.
- Gill PS, Harrington W Jr, Kaplan MH, et al Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995;332:1744–1748.